| http://www.w3.org/ns/prov#value | - February 7, 2005 Speedel Pharma announced positive results from phase I studies a pair of their investigational rennin inhibitors, SPP630 and SPP635, for the treatment of hypertension and protection of end-organs including the heart and kidneys.
|
